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Abstract
Background: The anticancer drug, 6-mercaptopurine (6MP) is subjected to metabolic clearance
through xanthine oxidase (XOD) mediated hydroxylation, producing 6-thiouric acid (6TUA),
which is excreted in urine. This reduces the effective amount of drug available for therapeutic
efficacy. Co-administration of allopurinol, a suicide inhibitor of XOD, which blocks the
hydroxylation of 6MP inadvertently enhances the 6MP blood level, counters this reduction.
However, allopurinol also blocks the hydroxylation of hypoxanthine, xanthine (released from dead
cancer cells) leading to their accumulation in the body causing biochemical complications such as
xanthine nephropathy. This necessitates the use of a preferential XOD inhibitor that selectively
inhibits 6MP transformation, but leaves xanthine metabolism unaffected.
Results: Here, we have characterized two such unique inhibitors namely, 2-amino-6-hydroxy-8-
mercaptopurine (AHMP) and 2-amino-6-purinethiol (APT) on the basis of IC50 values, residual
activity in bi-substrate simulative reaction and the kinetic parameters like Km, Ki, kcat. The IC50
values of AHMP for xanthine and 6MP as substrate are 17.71 ± 0.29 μM and 0.54 ± 0.01 μM,
respectively and the IC50 values of APT for xanthine and 6MP as substrates are 16.38 ± 0.21 μM
and 2.57 ± 0.08 μM, respectively. The Ki values of XOD using AHMP as inhibitor with xanthine and
6MP as substrate are 5.78 ± 0.48 μM and 0.96 ± 0.01 μM, respectively. The Ki values of XOD using
APT as inhibitor with xanthine and 6MP as substrate are 6.61 ± 0.28 μM and 1.30 ± 0.09 μM. The
corresponding Km values of XOD using xanthine and 6MP as substrate are 2.65 ± 0.02 μM and 6.01
± 0.03 μM, respectively. The results suggest that the efficiency of substrate binding to XOD and its
subsequent catalytic hydroxylation is much superior for xanthine in comparison to 6MP. In
addition, the efficiency of the inhibitor binding to XOD is much more superior when 6MP is the
substrate instead of xanthine. We further undertook the toxicological evaluation of these inhibitors
in a single dose acute toxicity study in mice and our preliminary experimental results suggested that
the inhibitors were equally non-toxic in the tested doses.
Conclusion: We conclude that administration of either APT or AHMP along with the major anti-
leukemic drug 6MP might serve as a good combination cancer chemotherapy regimen.
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Background
6MP, an analog of hypoxanthine was first among the thi-
opurine series found to be useful as an anticancer drug to
treat ALL, the most common malignancy affecting chil-
dren and other leukemias [1,2]. 6MP is taken up by the
cell and is transformed into an active metabolite 6-thio-
inosine monophosphate, an inhibitor of DNA synthesis,
by the target enzyme hypoxanthine-guanine phosphori-
bosyltransferase (HGPRT) using phosphoribosyl-pyro-
phosphate (PRPP) as a co-substrate [2,3]. 6MP is also
inadvertently being utilized by another enzyme XOD
leading to the generation of an inactive metabolite, 6TUA
which is excreted in urine [4,5]. Levels of XOD expression
varies from tissue to tissue and is also known to be over-
expressed in tumors [6-10]. So, in such cases, when the
anticancer drug 6MP is administered, it would possibly
lead to more metabolic transformation of 6MP. XOD cat-
alyzes a two-step hydroxylation reaction of 6MP, leading
to formation of 8-OH-6MP first and subsequently to
6TUA (Figure 1).
The wasteful degradation of 6MP by XOD suggested that
it is highly essential to minimize this catabolic pathway by
the use of a XOD inhibitor. Previous reports indicated that
semicarbazide could inhibit XOD and XDH activities in
vitro as well as in vivo but the inhibition in vivo was less
than 50% at doses that produced significant toxic effects
[6].
Then, allopurinol, a pyrazolopyrimidine derivative and
an analog of hypoxanthine, was employed as a part of
combination cancer therapy along with 6MP and was
found to result in a noticeable drop in the pace of catabo-
lism of 6-substituted purines including 6MP as well as
potentiate the antitumor and immunosuppressive proper-
ties of 6MP upto three to four-folds [6,11,12]. Allopurinol
is a non-specific suicide inhibitor of XOD available in
market for the treatment of gout, caused by the accumula-
tion of uric acid crystals in the joints and tissues [13-15].
XOD is an important purine metabolism pathway enzyme
which catalyzes the oxidative hydroxylation of the natural
purine, hypoxanthine to xanthine to finally uric acid
which is excreted in the urine [16-18] (Figure 2). Allopu-
rinol usage in the combination chemotherapy with 6MP
increases plasma concentration of the anticancer drug
allowing the reduction in the large 6MP dose to almost
25% [19-21]. On the other hand, allopurinol displays cer-
tain biochemical complications; the most important
amongst these is leading to the accumulation of natural
purines hypoxanthine and xanthine, as along with 6MP,
allopurinol also inhibits the natural hydroxylation path-
way of hypoxanthine and xanthine to uric acid. This accu-
mulation of natural purines leads to xanthine
nephropathy [22]. Furthermore, a huge amount of reac-
tive oxygen species (ROS) is generated with the adminis-
tration of allopurinol [23].
So, alternatively a substrate specific inhibitor along with
administration of this multipotential drug, 6MP must be
used. Diphenyleneiodonium chloride has been reported
as the preferential inhibitor of NAD(P)H oxidase as it
inhibits the NADH oxidation more effectively than of
NADPH [24]. Human PC4 is also been reported as a sub-
strate specific inhibitor of the RNA Polymerase II phos-
phorylation [25]. Inspite of the humungous progress
towards the development of XOD inhibitors to date
[6,11,26-30], there has been no report of any such sub-
strate specific inhibitor that selectively prevents 6MP from
being wastefully transformed into 6TUA against natural
purines. In the present work, we have discussed the action
of two such preferential XOD inhibitors.
Results
A preferential XOD inhibitor is the one which will inhibit
6MP from being metabolized by the action of XOD while
enzymatic hydroxylation of xanthine to uric acid is con-
tinued. The hydroxylation reaction of hypoxanthine
forming uric acid and 6MP forming 6TUA has no com-
mon intermediates (Figures 1 and 2).
IC50 determination
A few purine and pyrazolo pyrimidine-based compounds
were screened for inhibitory property against XOD-cata-
lyzed hydroxylation using xanthine and 6MP as substrates
(data not shown). 10 μM of either of the substrates and
2.8 U/ml of XOD were taken for the IC50 determination
Scheme showing oxidative hydroxylation of hypoxanthine to  xanthine to uric acid Figure 2
Scheme showing oxidative hydroxylation of hypoxanthine to 
xanthine to uric acid.
Scheme showing oxidative hydroxylation of 6-mercaptopu- rine to 6-thioxanthine to 6-thiouric acid Figure 1
Scheme showing oxidative hydroxylation of 6-mercaptopu-
rine to 6-thioxanthine to 6-thiouric acid.BMC Biochemistry 2007, 8:8 http://www.biomedcentral.com/1471-2091/8/8
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(Table 1). IC50 values of allopurinol for the enzymatic
conversion of xanthine to uric acid and 6MP to 6TUA are
found to be almost same (2.36 ± 0.03 and 1.92 ± 0.03
μM) and therefore, suggest that allopurinol is equally effi-
cient in inhibiting enzymatic conversion of both xanthine
to uric acid and 6MP to 6TUA formation. Since allopuri-
nol is a suicide inhibitor of XOD and the inhibition devel-
ops time-dependently [31], so the IC50  value of
allopurinol was calculated for the late phase as well by
carrying out the reaction for 60 min and the IC50 values of
allopurinol for XOD corresponding to the substrates
hypoxanthine and xanthine were 0.55 ± 0.45 and 1.65 ±
0.25 μM, respectively. While for 6MP, the IC50 values were
already calculated from 60 min reaction. Among many
compounds tested, two purine-based compounds
namely, AHMP and APT demonstrated a lower IC50 value
for the 6MP to 6TUA reaction (0.54 ± 0.01 μM and 2.57 ±
0.08  μM, respectively), although showed a reasonably
higher IC50 value for the xanthine to uric acid formation
reaction (17.71 ± 0.29 μM and 16.38 ± 0.21 μM, respec-
tively). The lower IC50 values for 6MP hydroxylation than
xanthine indicate that AHMP and APT inhibit hydroxyla-
tion of 6MP and xanthine with variable efficiencies. These
two purine-based compounds are found to be showing no
such difference in the IC50 value in the first and the late
phases and none were found to be XOD substrates. How-
ever, like allopurinol, the recently discovered XOD inhib-
itors, 6-(N-benzoylamino)purine [29] and also 4-
aminopyrazolo 3, 4-d pyrimidine (APP) [30] did not
exhibit any preferential inhibition of the 6MP hydroxyla-
tion over xanthine. The results imply that the structure of
the inhibitor plays a major role in regulating this preferen-
tial inhibition mechanism.
We also monitored the substrate-induced enzymatic elec-
tron transfer to the acceptors like 2,6-dichlorophenol
indophenol (DCPIP) and cytochrome c and found that
these two preferential inhibitors did not release either any
electrons or generate any ROS on interaction with XOD
while allopurinol led to substrate-induced enzymatic elec-
tron transfer via DCPIP (data not shown) [29,30]. Some
researchers report the generation of superoxides from
allopurinol in large amounts [23].
In vitro bi-substrate-inhibitor-enzyme simulation
In order to determine the extent of enzymatic hydroxyla-
tion of xanthine and 6MP into their corresponding prod-
ucts when the two substrates were present together in the
same reaction mixture, we carried out a bi-substrate simu-
lative experiment.
Percent residual activity for generation of uric acid and
6TUA was determined in the presence of various concen-
trations of AHMP, APT and allopurinol (Table 2). XOD-
mediated hydroxylation reaction of xanthine and 6MP
(bi-substrate) led to generation of uric acid and 6TUA
with progress of time, as shown in Figure 3. Absorption
spectra of the time dependent XOD-mediated bi-substrate
reaction in the presence of APT and AHMP are depicted in
Figure 4 and Figure 5, respectively. Almost complete inhi-
bition of 6MP hydroxylation while little inhibition of the
xanthine hydroxylation reaction was achieved in the pres-
ence of 5 μM APT and 2 μM AHMP (Here, variable inhib-
itor concentrations were chosen depending on different
IC50 values for the two substrates). Accounting for the per-
centage inhibition using these inhibitors, we found that
using 2.5 μM allopurinol, the uric acid and 6TUA forming
residual enzyme activity was 30% and 16%, respectively.
Using 2.5 μM APT, the residual enzyme activity for xan-
thine and 6MP hydroxylation was reduced to 80% and
25%, respectively and while using 2.5 μM AHMP it
resulted in residual 64% uric acid formation activity and
18% 6TUA formation.
Therefore, the results suggest that when the two sub-
strates, 6MP and xanthine are present together along with
either of the preferential inhibitors, the conversion of xan-
thine to uric acid is more favored than 6MP to 6TUA con-
version. The results also suggest that a critical
concentration of the inhibitor could be used to effectively
inhibit the enzymatic conversion of 6MP to 6TUA in the
branched pathway. A similar invitro tri-substrate simula-
tive studies was carried out with three substrates of XOD
namely, hypoxanthine, xanthine and 6MP in the absence
and presence of preferential inhibitors. Identical results
corresponding to the preferential inhibitors were
obtained indicating the discriminatory inhibition of the
6MP to 6TUA conversion and not hypoxanthine to uric
acid conversion by the action of AHMP and APT (data not
shown).
Mechanism of inhibition of Xanthine oxidase by AHMP 
and APT
To study mechanism of inhibition and distinguish the
interaction of XOD with the substrates, xanthine and 6MP
and inhibitors, AHMP and APT; we studied the steady-
state kinetics of XOD with respect to the substrates and
inhibitors. The double reciprocal Lineweaver Burk (LB)
plots were drawn to find the mechanism of inhibition of
XOD by APT and AHMP (Figure 6, 7, 8, 9). The Km, Ki
1,
KI
1,  Ki
2,  KI
2 and  kcat values, and inhibitory mechanism
exhibited by APT and AHMP are all depicted in Table 3.
Figure 6 depicts the LB plot of the steady-state inhibition
with increasing APT concentrations, which show straight
lines meeting at a point on Y-axis. Mechanistically, this
type of inhibition is interpreted as competitive. Structur-
ally speaking, we observe that the 8th position in both
xanthine and APT is free for hydroxylation facing the Mo
site of XOD. Also, both APT and xanthine has substitutionBMC Biochemistry 2007, 8:8 http://www.biomedcentral.com/1471-2091/8/8
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at the same positions, i.e. 2nd and 6th. Therefore, it seems
that xanthine and APT compete for XOD active site. Con-
sequently, it becomes evident that APT will bind to XOD
at its substrate binding site. The Ki1 value estimated from
the LB plot using the equation (1) [mentioned in Methods
section] were equivalent to 6.6 ± 0.28 μM with respect to
xanthine (Table 3).
Figure 7 projects a LB plot of steady-state inhibition of
XOD using 6MP as substrate with increasing APT concen-
trations, suggesting a conventional competitive inhibition
mechanism. Structural explanations illustrate that 8th
position is open for action in both 6MP and APT in front
of the Mo site of XOD. The Ki
1 value determined from the
LB plot using the equation (1) [mentioned in Methods
section] was found to be 1.30 ± 0.09 μM (Table 3).
AHMP also showed signs of efficiently inhibiting the
XOD-catalyzed 6MP catabolic reaction than the xanthine
hydroxylation reaction. Figure 8 demonstrates the LB plot
of the steady-state inhibition of XOD using xanthine as
substrate with increasing AHMP concentrations, illustrat-
ing the mixed type of inhibition like known XOD inhibi-
tors, BOF-4272, Pd+2, Y-700, Morin and Galagin, [32-35].
The Ki
2 and KI
2 values of 5.78 ± 0.48 μM (competitive) and
6.24 ± 0.04 μM (non-competitive) were calculated from
the LB plot using the equation (4) and (5) [mentioned in
Methods section]. Its non-competitive inhibition prop-
erty can be explained on the basis that 8th position is occu-
pied by SH group in AHMP, which is found free in
xanthine. Besides, the presence of NH2 group at 2nd posi-
tion in AHMP in place of an OH group in xanthine makes
it faultless contender to bind at any site other than active
site on XOD. And its competitive inhibition property may
be due to the presence of OH group present at the 6th posi-
tion in both AHMP and xanthine and thus, they compete
for the enzyme active site.
For XOD-catalyzed 6MP catabolic reaction, AHMP shows
evidence of a mixed inhibition mechanism (Figure 9)
Table 1: Table showing IC50 values of different purine and allopurinol-based compounds for XOD inhibition.
(μM ± SEM)
Inhibitor Hypoxanthine Xanthine 6MP
ALLOPURINOL 0.91 ± 0.01 2.36 ± 0.03 1.92 ± 0.03
APT 7.28 ± 0.17 16.38 ± 0.21 2.57 ± 0.08
AHMP 5.08 ± 0.04 17.71 ± 0.29 0.54 ± 0.01
APP 6.79 ± 0.28 20.76 ± 0.84 12.86 ± 0.69
The reaction mixture comprised of 1 ml of 0.2 M, sodium phosphate buffer pH 7.4 containing 10 μM of one of the substrates namely, hypoxanthine, 
xanthine or 6MP. The concentration range of allopurinol and APP were 0–3 μM and 0–100 μM, respectively for all three substrates. The 
concentration range of AHMP and APT were 0–100 μM and 0–50 μM, respectively for all three substrates. The reaction was initiated by the 
addition of 2.8 U/ml of bovine XOD.
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indicating that native XOD is capable of forming two
inhibitory complexes with AHMP. Occurrence of SH
group at positions 6th in 6MP and at 8th in AHMP makes
the latter an ideal applicant to compete with 6MP for
active site and consequent inhibition of XOD. However,
the existence of extra groups (OH and NH2) in AHMP at
two positions makes it attach at a site other than the active
site of the enzyme. Ki
2 and KI
2 values for inhibition were
calculated out to be 0.96 ± 0.01 μM (competitive) and
0.98 ± 0.06 μM (non-competitive) using the equations (4)
and (5) [mentioned in Methods section]. The values of
the two inhibition constants of AHMP do not differ much,
indicating that the nature of the coordination of the
AHMP for the competitive and non-competitive binding
sites is similar.
Comparison and evaluation of acute toxicity
Single dose acute toxicity was evaluated for AHMP and
APT and compared with allopurinol, the standard drug
used in the present investigation. No differences in gen-
eral behavioral toxicity and no mortality were observed
after the administration of the compounds. No significant
changes in the initial and final body weight were observed
for any of the compounds. The weekly food intake
decreased for the groups treated with AHMP, APT and
allopurinol as compared to vehicle treated groups. How-
ever, AHMP and APT treated groups food intake was mar-
ginally less as compared to allopurinol treated groups.
Gross necropsy revealed no changes in vital organs. No
difference in organ weight was observed as compared with
the control groups.
Table 2: Bi-substrate simulative experiment.
Inhibitor (μM) % Activity with xanthine as substrate % Activity with 6MP as substrate
ALLOPURINOL
0.5
1.0
2.5
95 ± 1.09
68 ± 3.51
30 ± 1.04
83 ± 1.05
48 ± 1.07
16 ± 1.05
APT
0.5
1.0
2.5
96 ± 1.00
90 ± 0.51
80 ± 2.50
73 ± 2.50
66 ± 3.01
25 ± 2.06
AHMP
0.5
1.0
2.5
90 ± 1.09
85 ± 2.06
64 ± 1.02
59 ± 4.01
47 ± 4.01
18 ± 2.08
The reaction mixture comprised of 1 ml of 0.2 M, sodium phosphate buffer pH 7.4 containing 10 μM of both xanthine and 6MP. The concentration 
range of allopurinol was 0–2.5 μM. The concentration range of AHMP was 0–3 μM. The concentration range of APT was 0–10 μM. The reaction 
was initiated by the addition of 2.8 U/ml of bovine XOD.
Bi-substrate reaction of XOD-mediated hydroxylation of  xanthine and 6MP Figure 3
Bi-substrate reaction of XOD-mediated hydroxyla-
tion of xanthine and 6MP. The reaction mixture com-
prised of 1 ml of 0.2 M, sodium phosphate buffer pH 7.4 
containing 10 μM of both xanthine and 6MP. The reaction 
was initiated by the addition of 2.8 U/ml of bovine XOD and 
observed for 20 min.
Bi-substrate reaction of XOD-mediated hydroxylation of  xanthine and 6MP in presence of APT Figure 4
Bi-substrate reaction of XOD-mediated hydroxyla-
tion of xanthine and 6MP in presence of APT. The 
reaction mixture comprised of 1 ml of 0.2 M, sodium phos-
phate buffer pH 7.4 containing 10 μM of both xanthine and 
6MP. 5 μM APT was taken. The reaction was initiated by the 
addition of 2.8 U/ml of bovine XOD and observed for 20 
min.BMC Biochemistry 2007, 8:8 http://www.biomedcentral.com/1471-2091/8/8
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Discussion
Inhibition mechanism of Xanthine oxidase by AHMP and 
APT
Mixed-type inhibition includes competitive and non-
competitive inhibition. Competitive inhibition is exhib-
ited when the substrate and the inhibitor compete for the
substrate binding active site but non-competitive inhibi-
tion is exhibited when the inhibitor binds at a site other
than the active site. Following the crystallographic studies
performed on XOD, no peripheral binding site has been
reported in XOD catalytic subunits [36,37]. For the past
50 years, it was assumed that the two XOD subunits carry
out catalysis independently but a recent report [38] on the
cooperative binding of the two subunits of XOD may sup-
port the non-competitive inhibition mechanism exhib-
ited by AHMP. AHMP possibly interacts with the XOD
domains distal to the substrate binding site also other
than the substrate binding site, thereby possibly resulting
in allosteric effects that attenuate the enzymatic activity.
Since XOD acts via a ping-pong mechanism, alternating
between the oxidized and reduced forms [39], so another
plausible explanation for the mixed inhibition exhibited
by AHMP is that AHMP binds to both the oxidized and
reduced form of XOD. Allopurinol (a known weak com-
petitive inhibitor) and nitric oxide are known to strongly
bind to the reduced state of XOD [40,41]. APT being a
competitive inhibitor thus, might not be binding to the
oxidized state but to the reduced state of XOD. The differ-
ence in the mechanism of inhibition exhibited by AHMP
and APT must be possible due to the structural dissimilar-
ities between the two inhibitors.
Biochemical explanations of the efficiency of binding of 
substrate and inhibitor to Xanthine oxidase
The Km, kcatand Ki values of XOD corresponding to the
substrates, 6MP and xanthine and the inhibitors, APT and
AHMP behave as the factors indicating the type of their
binding and catalytic interactions with the enzyme. In the
biochemical reaction,
where, E is enzyme, S is substrate, P is product, k1 and k3
are the rate constants for the forward reactions and k2 is
the rate constant for the backward reaction.
By definition, Km of any biochemical reaction can be
mathematically expressed in terms of rate constant [42] as
Km = (k2+ k3)/k1
Lower Km implies a lower dissociation of ES into E+S or
E+P while higher Km implies higher dissociation of ES into
E+S or E+P. While looking at the turnover number (kcat) of
xanthine and 6MP, we found that it is the dissociation of
the corresponding ES complexes into E+P and not E+S.
The inhibition constant Ki on the other hand can be
defined [42] as:
Table 3: Table showing kinetic parameters of APT and AHMP.
Inhibitor Substrate Km (μM) Mechanism of inhibition Ki (μM) kcat(min)-1
APT Xanthine 2.65 ± 0.02 Competitive 6.61 ± 0.28 114.54 ± 0.24
6MP 6.01 ± 0.03 Competitive 1.30 ± 0.09 2.85 ± 0.02
AHMP Xanthine 2.71 ± 0.05 Mixed 5.7 ± 0.48(Ki
2) (Competitive)
6.24 ± 0.04 (KI
2) (Non-competitive)
128.57 ± 0.45
6MP 4.89 ± 0.04 Mixed 0.96 ± 0.01(Ki
2) (Competitive)
0.98 ± 0.06 (KI
2) (Non-competitive)
3.64 ± 0.04
The reaction mixture comprised of 1 ml of 0.2 M, sodium phosphate buffer pH 7.4 containing 10 μM of either xanthine or 6MP. The reaction was 
initiated by the addition of 2.8 U/ml of bovine XOD.
Ki
2 = Inhibition constant for competitive inhibition mechanism exhibited by AHMP
KI
2 = Inhibition constant for non-competitive inhibition mechanism exhibited by AHMP
Bi-substrate reaction of XOD-mediated hydroxylation of  xanthine and 6MP in presence of AHMP Figure 5
Bi-substrate reaction of XOD-mediated hydroxyla-
tion of xanthine and 6MP in presence of AHMP. The 
reaction mixture comprised of 1 ml of 0.2 M, sodium phos-
phate buffer pH 7.4 containing 10 μM of both xanthine and 
6MP. 2 μM AHMP was taken. The reaction was initiated by 
the addition of 2.8 U/ml of bovine XOD and observed for 20 
min.BMC Biochemistry 2007, 8:8 http://www.biomedcentral.com/1471-2091/8/8
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where, I is inhibitor, k1 is the rate constant for the forward
reaction and k2 is the rate constant for the backward reac-
tion
Ki = k2/k1
Lower Ki implies lower dissociation of EI complex into E
+ I and higher association of E and I, while higher Ki
means higher dissociation of EI complex and lower asso-
ciation of E and I.
Km and kcat values of XOD using 6MP as substrate implied
that the conversion of XOD-6MP (ES) complex into its
product 6TUA is slower as its turnover number is much
lower (2.85 ± 0.02 μM/min) than the conversion of XOD-
xanthine complex into its corresponding product (Table
3). Additionally, XOD-6MP (ES) complex is also less
favored as the Km in this case is high (6.01 ± 0.03 μM).
Considering xanthine as substrate of XOD however, the
situation is different. The high kcat (114.54 ± 0.24 μM/
min) indicates that the forward reaction of xanthine-XOD
into uric acid (ES into E+P) is faster as compared to its dis-
sociation into other counterpart (E+S) and lower Km (2.65
± 0.02 μM) indicates that xanthine-XOD (ES) complex
formation is also more favored. Therefore, the higher
turnover of xanthine to uric acid conversion in compari-
son to 6MP to 6TUA conversion is favored only if the ES
complex formation is favored rather than its dissociation
into E+S which does not occur in case of 6MP-XOD inter-
action.
Now, we can presume a correlationship of Km and Ki of
XOD with respect to xanthine and 6MP, respectively.
When 6MP and APT (or AHMP) interact with XOD, lower
Ki implies stronger XOD-AHMP (EI) complex formation
and AHMP will more efficiently dissociate 6MP from
XOD active site while higher Km implies less favored XOD-
6MP (ES) complex formation and subsequently, slower
6TUA formation, further supporting that XOD and 6MP
(E+S) formation is much preferred in 6MP as compared to
xanthine. However, when xanthine and APT (or AHMP)
interact with XOD, higher Ki implies weaker and slower
rate of formation of XOD-AHMP (EI) complex and the
inhibitor AHMP is not efficient in displacing xanthine
from XOD and thus, the enzymatic hydroxylation of xan-
thine continues while lower Km implies more favored for-
mation of XOD-xanthine (ES) complex and subsequently,
higher formation of uric acid.
It will be right to say that these preferential inhibitors,
AHMP and APT displace 6MP efficiently from weak XOD-
6MP complex while AHMP and APT are incapable of dis-
placing xanthine from strong xanthine-XOD complex
Lineweaver-Burk plot of inhibition of XOD-mediated 6MP  hydroxylation by APT Figure 7
Lineweaver-Burk plot of inhibition of XOD-mediated 
6MP hydroxylation by APT. The reaction mixture com-
prised of 1 ml of 0.2 M, sodium phosphate buffer pH 7.4 con-
taining varying concentrations of 6MP ranging from 2, 5, 8, 
10, 15 and 20 μM. APT concentrations were [I] = 0 μM (●), 
[I] = 2 μM (❍), [I] = 4 μM (▼). The reaction was initiated by 
the addition of 2.8 U/ml of bovine XOD.
Lineweaver-Burk plot of inhibition of XOD-mediated xan- thine hydroxylation by APT Figure 6
Lineweaver-Burk plot of inhibition of XOD-mediated 
xanthine hydroxylation by APT. The reaction mixture 
comprised of 1 ml of 0.2 M, sodium phosphate buffer pH 7.4 
containing varying concentrations of xanthine ranging from 2, 
5, 8, 10 and 20 μM. APT concentrations were [I] = 0 μM (●), 
[I] = 5 μM (❍), [I] = 10 μM (▼), [I] = 15 μM (Ќ). The reac-
tion was initiated by the addition of 2.8 U/ml of bovine XOD.BMC Biochemistry 2007, 8:8 http://www.biomedcentral.com/1471-2091/8/8
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(Figures 10 and 11). In other words, substrate hit and
inhibitor displacement takes place from XOD active or
non-active site for xanthine-XOD reaction but inhibitor
hit and substrate displacement for 6MP-XOD reaction. It
can be stated that the 6MP to 6TUA hydroxylation is dis-
criminately inhibited in contrast to xanthine to uric acid
hydroxylation by these preferentially inhibitors.
Conclusion
In the present study, we have attempted to search a prefer-
ential XOD inhibitor which would discriminately inhibit
the 6MP to 6TUA reaction rather than xanthine to uric
acid reaction because allopurinol employed in combina-
tion with 6MP as cancer chemotherapy inhibits enzymatic
hydroxylation of hypoxanthine, xanthine, and 6MP with
equal efficiency, which leads to the development of some
biochemical problems like xanthinuria [43] and xanthine
nephropathy [44]. Furthermore, hypoxanthine when
accumulated in the body competes with 6MP for the
action by HGPRT [45]. Additionally, it has been observed
that the administration of allopurinol, as a component of
combination chemotherapy leads to the depletion in the
intracellular pool of phosphoribosyl pyrophosphate
(PRPP) as allopurinol is converted to allopurinol ribonu-
cleotide by HGPRT using PRPP. The allopurinol ribonu-
cleotide possesses further the potential for inhibition of
PRPP amidotransferase and orotidylic acid decarboxylase
[45-49]. Conversion to the allopurinol nucleoside by
purine nucleoside phosphorylase has also been reported
[50].
We found two such preferential inhibitors namely, APT
and AHMP. The extent of inhibition is dependent on the
binding interactions of the respective substrates and
inhibitors with the enzyme.
It is important to mention here that APT is a known anti-
cancer drug with HGPRT as its target enzyme. Therefore,
use of APT as a preferential XOD inhibitor along with
6MP may increase the efficiency and reduce the dosage of
6MP. We conclude that administration of either APT or
AHMP along with the major anti-leukemic drug 6MP
might serve as a good combination cancer chemotherapy
regimen. To the extent that adverse consequences of allop-
urinol therapy may relate to actions of this purine analog
compound exclusive of XOD inhibition, the selectivity of
AHMP and APT may lessen the risk for at least some of the
untoward effects of current combined chemotherapy in
patients with cancer. To the best of our knowledge, we
have for the first time developed such preferential inhibi-
tors of XOD based on the difference in the interactions
with its substrate and inhibitor.
Methods
AHMP and APT both were purchased from Lancaster, UK.
Bovine milk XOD was procured from Calbiochem (La
Lineweaver-Burk plot of inhibition of XOD-mediated 6MP  hydroxylation by AHMP Figure 9
Lineweaver-Burk plot of inhibition of XOD-mediated 
6MP hydroxylation by AHMP. The reaction mixture 
comprised of 1 ml of 0.2 M, sodium phosphate buffer pH 7.4 
containing varying concentrations of 6MP ranging from 5, 8, 
10 and 20 μM. AHMP concentrations were [I] = 0 μM (●), 
[I] = 0.5 μM (❍), [I] = 1.5 μM (▼). The reaction was initiated 
by the addition of 2.8 U/ml of bovine XOD.
Lineweaver-Burk plot of inhibition of XOD-mediated xan- thine hydroxylation by AHMP Figure 8
Lineweaver-Burk plot of inhibition of XOD-mediated 
xanthine hydroxylation by AHMP. The reaction mixture 
comprised of 1 ml of 0.2 M, sodium phosphate buffer pH 7.4 
containing varying concentrations of xanthine ranging from 1, 
2, 5, 8, 10 and 20 μM. AHMP concentrations were [I] = 0 
μM(●), [I] = 2 μM (❍), [I] = 5 (▼), [I] = 10 μM (Ќ). The 
reaction was initiated by the addition of 2.8 U/ml of bovine 
XOD.BMC Biochemistry 2007, 8:8 http://www.biomedcentral.com/1471-2091/8/8
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Jolla, CA, USA). Hypoxanthine, xanthine and 6MP were
purchased from Sigma (St. Louis, MO, USA). Disodium
hydrogen phosphate and Sodium dihydrogen phosphate
were procured from Merck Inc. Ltd (Germany). The spec-
trophotometric experiments were performed on Perkin
Elmer's Lambda 25 dual beam spectrophotometer.
XOD activity was determined spectrophotometrically by
measuring uric acid formation at 293 nm with xanthine as
substrate [51] and 6TUA formation at 350 nm with 6MP
as substrate. One enzyme unit is defined as amount of
enzyme required to produce 1 μM uric acid per min per ml
reaction mixture from 10 μM of xanthine at 30°C, pH 7.4.
Equivalent concentration of XOD was found to be 35 nM
based on the molar extinction coefficient (Δε) of 36 mM-
1cm-1 at 450 nm [51]. In all the experiments, the enzyme
was added lastly to initiate the reaction. Δε value of uric
acid is 11 mM-1cm-1 at 293 nm [52] and Δε value of 6TUA
is 22 mM-1cm-1 at 350 nm.
The IC50 values were determined for all the purine and
pyrazolopyrimidine-based compounds. Percent inhibi-
tion of XOD was studied in terms of decrease in uric acid
and 6TUA formation as compared to the product forma-
tion in absence of inhibitor. GRAFIT software procured
from Erithacus Software Limited, UK, written by Dr R.J.
Leatherbarrow, was employed for calculating the IC50 val-
ues.
To appreciate the actual biochemical interactions carried
out by XOD in vivo with respect to its natural (xanthine)
and synthetic substrates (6MP), we designed a combined
competitive  in vitro simulative experiment wherein we
determined the percent residual activity for the formation
of uric acid and 6TUA by the co-presence of equimolar
concentrations (10 μM, which is higher than the Km of the
two substrates) of both the substrates of XOD (xanthine
and 6MP) and either of the two preferential inhibitors
(AHMP and APT). Percent residual activity of formation
of uric acid and 6TUA was determined by subtracting the
percentage inhibition from 100%. Km of XOD was deter-
mined for 6MP and xanthine from the Michaelis Menten
plot and the kcat was determined by using the formula kcat
= Vmax/Et, where Vmax is the maximum velocity attained by
a reaction and Et is the total enzyme concentration used in
the reaction. Km and kcat were determined in the absence of
the inhibitors. To determine the mechanism of inhibition
exhibited, LB plots were drawn using Sigma Plot 9.01 ver-
sion with Enzyme Kinetics module and the Ki was calcu-
lated using the following formulae,
For competitive inhibition,
-1/Km app = -1/Km (1+ [I]/Ki)( 1 )
For non-competitive inhibition,
Xanthine-XOD-Inhibitor interaction showing substrate hit  and inhibitor displacement Figure 11
Xanthine-XOD-Inhibitor interaction showing substrate hit 
and inhibitor displacement.
6-mercaptopurine-XOD-Inhibitor interaction showing inhibi- tor hit and substrate displacement Figure 10
6-mercaptopurine-XOD-Inhibitor interaction showing inhibi-
tor hit and substrate displacement.BMC Biochemistry 2007, 8:8 http://www.biomedcentral.com/1471-2091/8/8
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1/Vmax app = (1+ [I]/Ki)/Vmax  (2)
The modified LB equation for the mixed inhibition is
1/v = 1/Vmax app + Kmax app/Vmax app [S]0  (3)
where, Km app and Vmax app are defined by equations (4)
and (5).
Km app = Km {1+([I0]/Ki)}/{1+ ([I0]/KI)} (4)
Vmax app = Vmax/{1+ ([I0]/KI)} (5)
[I0] is the total concentration of the inhibitor, [S0] is the
total concentration of substrate, Km is the Michaelis con-
stant and Vmax is the maximum velocity of the reaction of
XOD with the substrates 6MP or xanthine. Km app is the
apparent Michaelis constant and Vmax app is the apparent
maximum velocity of the reaction of XOD with its sub-
strates. Ki and KI are the inhibition constants of the inhib-
itors [53,54].
Evaluation of acute toxicity of two discriminatory 
inhibitors
In order to evaluate the toxicity of the preferential inhibi-
tors of XOD, the single dose acute toxicity study was per-
formed for both the preferential inhibitors on swiss male
mice following a fourteen days observation period. The
body weight of the animal ranged from 25–30 gm. Three
different doses (2.5, 5, 10 mg/kg) for the two compounds
were selected, using allopurinol as the standard drug and
administered intravenously [55]. Parameters, e.g., body
weight, food intake, mortality, general behavioral toxicity
were observed after the administration of the compounds
for fourteen days. Gross necropsy of each animal of all
groups was conducted and organ weight was recorded
after the termination of the study.
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